Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for 2025-2034. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A) biologic activity (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic therapy approved for the treatment of human cancer. The drug was developed by F. Hoffmann-La Roche AG...
Report ID: 1073 |
Delivery: Immediate |
Published: October 2025 |
No. of Pages: 170
TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034. Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spo...
Report ID: 1072 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The Global Clinical Trial Services Market size is valued at USD 22.58 billion in 2023 and is predicted to reach USD 42.86 billion by the year 2031 at an 8.44% CAGR during the forecast period for 2024-2031. The services used by biopharmaceutical or pharmaceutical companies to conduct clinical trial either for the approval of a new drug or biologic or for the entry of new generic or biosimilar to the market is ...
Report ID: 1071 |
Delivery: Immediate |
Published: August 2024 |
No. of Pages: 180
The Deep Vein Thrombosis Market Size is valued at 958.11 Million in 2022 and is predicted to reach 1343.86 Million by the year 2031 at a 4.0 % CAGR during the forecast period for 2023-2031. Deep vein thrombosis (DVT) is a serious condition that occurs when clots forms in the deep veins of the body. The most dangerous complication of deep vein thrombosis is pulmonary embolism (PE), which can either be asymptomatic or symptomatic. Surgery and pr...
Report ID: 1070 |
Delivery: Immediate |
Published: February 2025 |
No. of Pages: 180
The Breast Cancer Market is expected to grow at an 8.8% CAGR during the forecast period for 2024-2031. Breast cancer start when cells in the breast begin to grow out of control. These cells form tumour that can often see on an x-ray. Breast cancer is the most common cancer among women, after skin cancer and second leading cause of cancer death in women after lung cancer. Breast cancer is broadly classified into two include non-invasive and...
Report ID: 1069 |
Delivery: Immediate |
Published: August 2024 |
No. of Pages: 140
The Etanercept Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an 17.8% CAGR during the forecast period for 2025-2034. Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rhe...
Report ID: 1068 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
The Ovarian Cancer Market is expected to grow at a 10.5% CAGR during the forecast period for 2024-2031. Ovarian cancer rank fifth in cancer deaths among women and accounting for more deaths than any other cancer of the female reproductive system. Previously it believed that cancer begin only in the ovaries, but recent evidence suggests that many ovarian cancer may start in the fallopian tubes. Factors can increase risk of cancer include ol...
Report ID: 1067 |
Delivery: Immediate |
Published: August 2024 |
No. of Pages: 180
The preceding decades have shown higher incidence and prevalence trends for cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. The number of new cancer cases is predicted to rise by 54% within the next two decades. In economically developing countries, adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, will gradually increase the burden of the tr...
Report ID: 1066 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 140
The Fragile X Syndrome Market Size is valued at 20.80 Million in 2022 and is predicted to reach 37.71 Million by the year 2031 at a 7.0 % CAGR during the forecast period for 2023-2031. Fragile X syndrome is a hereditary condition that causes a range of neurological problems, including cognitive impairment and learning disabilities. Males are more affected compare to females by this disorder. It causes delayed development of speech and lang...
Report ID: 1065 |
Delivery: Immediate |
Published: November 2024 |
No. of Pages: 180
The Global Endometrial Ablation Systems Market Size is valued at 3.27 Billion in 2023 and is predicted to reach 5.42 Billion by the year 2031 at a 6.8 % CAGR during the forecast period for 2024-2031. The device that is used by gynecologist to perform endometrial ablation on an outpatient basis are known as endometrial ablation systems. Endometrial ablation is a procedure that is used for the treatment of abnormal uterine bleeding (me...
Report ID: 1064 |
Delivery: Immediate |
Published: February 2024 |
No. of Pages: 180
Pharmaceuticals